Caliper Life Sciences — Xenogen — Merger or Acquisition (March 2006)
31 slides from Caliper Life Sciences's merger presentation, Mar 3, 2006
Slide 1: Transforming Life Sciences through Innovative Technologies
Transforming Life Sciences through Innovative Technologies Kevin Hrusovsky, President & CEO March 1, 2006
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes forward-looking statements, including financial projections. Reference to what we expect, believe, intend to do, plan, hope, estimate or other statements referring to future events or results are intended to identify those as forward- looking sta
Slide 3: Important Notice
Important Notice In addition to the foregoing, please note that Caliper intends to file a Registration Statement on Form S-4 in order to register the shares of its common stock and warrants to be issued to the former stockholders of Xenogen Corporation in the proposed merger between Caliper and Xeno
Slide 4: 2005: Another Year of Strong Financial Performance
2005: Another Year of Strong Financial Performance Exceeded Q4'05 goal of break even operating cash flow, $3M+ Exceeded year end cash goal with $32M vs. $25M street goal Achieved Q4 revenue guidance with $27M, 12% growth Exceeded EPS street consensus Completed accretive NS acquisition and announced
Slide 5: Building on Momentum Towards an Ambitious 2006
Building on Momentum Towards an Ambitious 2006 2003 - 2005 Accomplishments $35M EBITDA and $250M enterprise value gain Revenue growth 175%, reversed LabChip negative growth to positive 15%+ Cost Savings: $25M Revitalized R&D investment, target 18% of sales (40% funded) Mix shift toward aftermarket;
Slide 6: Historical Trends Show Dramatic Improvement
Historical Trends Show Dramatic Improvement EBITDA, as shown above, is a non-GAAP measure viewed by Caliper Management to track earnings trends. EBITDA excludes the effects of interest, depreciation, amortization of intangibles and deferred stock compensation, and restructuring charges. 2001 EPS exc
Slide 7: Caliper Life Sciences to Acquire Xenogen
February 13, 2006 News: Caliper Life Sciences to Acquire Xenogen Xenogen profile Leader in in-vivo imaging systems and pre-clinical services Strong IP position in bio-photonics imaging 2005 revenues = $39.7M, 28.4% growth from 2004 Why Xenogen? Caliper entry into high-growth optical imaging market C
Slide 8: The Merger Offers Strategic and Financial Benefits
The Merger Offers Strategic and Financial Benefits Revenue Synergies Customer synergy: academic / commercial and geographic Total company growth rate expected at 10% - 15% Critical Mass Expands base over 40% (2005 pro forma) Leverage manufacturing, commercial, G&A and aftermarket infrastructure Expe
Slide 9: Profile of the New Company: Products and Services
Enabling Higher Relevance / Productivity Experimentation Products Liquid Handling and Automation LabChip Technologies In vitro Drug Discovery Services In vivo Products and Services Profile of the New Company LabChip Liquid handling & automation in vitro services Pre-Xenogen 30 60 10 Revenue Outlook
Slide 10: Profile of the New Company: Markets and Customers
Enabling Higher Relevance / Productivity Experimentation Markets Drug Discovery and Development $1.7B market, growing 5-8%, approx 5%+ share 2005 revenue approx. $80M; Expect 15%+/- growth in 2006 (40% w/ XGEN) Molecular Diagnostics $1.5B market growing 20%, new entrant 2005 license, contract revenu
Slide 11: Xenogen is a Defining Step in Caliper's Evolution
Xenogen is a Defining Step in Caliper's Evolution Founded 1981 1998 1999 Founded 1998 1999 2001 July 2003 2003 October 2005 1995 2001 1996 2004 July 2005 2005 2001 2005 May 2006 (expected)
Slide 12: Blue-Chip Customers have Guided Caliper's Development
Blue-Chip Customers have Guided Caliper's Development Top 15 customers are less than 50% of total revenues Largest customer is 10% of total revenues Human Genome Project Representative list of top 15 customers
Slide 13: Our Customers Face Declining Productivity
Our Customers Face Declining Productivity "Low hanging fruit" exhausted Current opportunities require more complex biology/MOA Diseases for investigation are more complex Regulatory oversight is more stringent Primary failure mode: Safety & Side Effects # NME Approvals Productivity Gap Sources: FDA,
Slide 14: Over-reliance on Early Stage in vitro Experimentation Creates Gaps
Over-reliance on Early Stage in vitro Experimentation Creates Gaps in Drug Pipeline Notable trends in life science research Growing divide between in vitro and in vivo work Data quality and relevance of in vitro and in vivo work under question Molecular basis and system biology pursued to better pre
Slide 15: Researchers Focused on Bridging in vitro and in vivo Experimentation
Life Science Researchers are Focused on Bridging in vitro and in vivo Experimentation to Close these Gaps "We want as much consistency from in vitro to in vivo studies as possible, so we can be assured that what we see happening in the test tube is the same as what we see in animals. For example, we
Slide 16: Caliper's Strategy: Shift the Drug Discovery Value Chain
In Vitro Molecule Analysis Cellular Analysis Humans Animal Models 1,000 days 10 days 10/day 1,000,000/day THROUGHPUT and COST/DATA POINT Relevance 1,000/day $10,000,000 $100,000 $1,000 $10 $0.01 PATIENT MOLECULE Caliper's Strategy: Shift the Drug Discovery Value Chain 100,000/day $0.1 Strategic Miss
Slide 17: Caliper's Strategy: Shift the Drug Discovery Value Chain
In Vitro Molecule Analysis Cellular Analysis Humans Animal Models 1,000 days 10 days 10/day 1,000,000/day THROUGHPUT and COST/DATA POINT Relevance 1,000/day $10,000,000 $100,000 $1,000 $10 $0.01 PATIENT MOLECULE Caliper's Strategy: Shift the Drug Discovery Value Chain 100,000/day $0.1 GeneChip Human
Slide 18: Innovative Technologies Enhance the Relevancy of in vitro Results
100k data points/day Innovative Technologies Enhance the Relevancy of in vitro Results Ion Channels GPCRs Proteases Kinases Allegra (r) 100,907 Flavopiridol Lovenox (r) Delix (r) Factor Xa inhibitors Cariporide HP - - 184 Targets of the top 200 drugs 25 $21.3 billion 15 $16.8 billion 2 $7.11 billion
Slide 19: Technology With LabChip Technology
T+ T+ T+ T+ T+ T+ 384 Technology With LabChip 384 Technology
Slide 20: LabChip: x1000 plates per day
T + T+ T+ T+ T+ T+ x1000 plates per day
Slide 21: Industry Attention to Microfluidic Technology has Accelerated
1997 1998 1999 2000 2001 2002 2003 2004 2005 Number of Citations 5 5 16 47 91 146 260 620 760 Number of Citations Industry Attention to Microfluidic Technology has Accelerated
Slide 22: Rapidly Growing LabChip Installed Base
Rapidly Growing LabChip Installed Base Demonstrates Caliper Direct Channel Success *Includes LabChip 3000, Caliper 250, Caliper 220, AMS 90, AMS 90 SE, LabChip 90; excludes Amphora Caliper 250 systems Total Units Placed* Year
Slide 23: "Caliper Driven" Program is Expanding the Reach of our Technologies
"Caliper Driven" Program is Expanding the Reach of our Technologies Experion launched in Q4 '04 New system under development Diagnostic license in 2005. Expect product sales in 2007 More than 1.5 million chips sold - New 5 year supply deal 2100 Bioanalyzer over 4000 units installed Launched 5100 ALP
Slide 24: Agilent and Bio-Rad Combined Chip Sales Relative to Installed Base
Agilent and Bio-Rad Combined Chip Sales Relative to Installed Base *Estimate
Slide 25: Strategic Acquisition of NovaScreen Rounds Out in vitro Strategy
Strategic Acquisition of NovaScreen Rounds Out Caliper's in vitro Strategy Caliper's in vitro Strategy Caliper's in vitro Strategy >650 Assays Today - GPCR's, Biochemical 1000 Assays 2007 - 200 kinase assays Strong growth potential Relatively low utilization 25% EBITDA and leverageable
Slide 26: Xenogen: Advanced Optical Imaging Systems
Xenogen: Advanced Optical Imaging Systems that Accelerate Drug Discovery and Development
Slide 27: Xenogen's in vivo Technologies Offer Unique Capabilities
Xenogen's in vivo Technologies Offer Unique Capabilities for Integrated Molecular Level Solutions
Slide 28: Vision for a New Company: Bridge in vitro - in vivo Gap
Vision for a New Company: Bridge in vitro - in vivo Gap to Provide Clinically Relevant Tools and Services Across the Discovery Spectrum Product families Applications Primary screening Kinase, phosphatase, protease assays Cell based assays Compound profiling in vivo screening & profiling Drug and met
Slide 29: Caliper's 2006 Priorities
Caliper's 2006 Priorities Close the Xenogen acquisition by mid-year Phased integration of Xenogen operations to achieve cost synergies Exploit distribution channel synergies, customer and geographic, to drive Imaging Products and LabChip revenues Expand reagent strategy and disease models to address
Slide 30: Financial Summary and Performance
Financial Summary and Performance 2005 performance is unaudited and presented for illustrative purposes only. EBITDA, as shown above, is a non-GAAP measure viewed by Caliper Management to track earnings trends. EBITDA excludes the effects of interest, depreciation, amortization of intangibles and de
Slide 31: Slide 31